<DOC>
	<DOCNO>NCT01497470</DOCNO>
	<brief_summary>The primary goal study determine custirsen effect way body distribute get rid paclitaxel , standard administer chemotherapy . The study also evaluate custirsen influence way body distribute get rid carboplatin ( another standard administer chemotherapy ) measure custirsen blood level cancer population . Finally , study evaluate safety tolerability add custirsen standard paclitaxel/carboplatin chemotherapy .</brief_summary>
	<brief_title>A Clinical Study Cancer Patients Investigate Potential Impact Custirsen , Blood Levels Chemotherapeutic Drug , Paclitaxel , When Given Together Part Treatment Regimen</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Confirmed diagnosis solid tumor refractory standard therapy amenable treatment establish curative palliative therapy paclitaxel carboplatin deem acceptable treatment investigator Males females ≥18 year age Life expectancy ≥12 week Minimum 1 lesion ECOG performance status 0 , 1 2 Adequate bone marrow reserve Adequate renal liver function Brain metastases symptomatic require ongoing treatment Major trauma surgery within last 2 month , acute infection within 2 week ( 14 day ) , radiotherapy , chemotherapy , immunotherapy hormonal therapy within past 4 week Persistent grade 2 great toxicity relate prior therapy Grade 2 great peripheral neuropathy Recent current use Cyp3A4 , Cyp2C8 Pgp inhibitor Recent current use CYP enzyme inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>custirsen</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cancer</keyword>
</DOC>